Known drug-drug interactions (DDIs) are responsible for 13 percent of adverse drug events and 4.8 percent of hospital admissions in older adults. Even these high figures may understate the true impact of DDIs because they include only the effects of known interactions. Many clinically important DDIs take years to discover. Given the widespread and growing use of multiple medications by persons with diabetes, there is tremendous potential for DDIs to occur in this population. Of the ten most commonly used second-line antidiabetic agents, five are insulin secretagogues, which, based on known metabolic pathways, may interact with many commonly- prescribed medications. DDIs involving insulin secretagogues can cause serious hypoglycemia, which can be immediately life-threatening and have cause long-term consequences. The broad objective of this project is to produce clinically-actionable knowledge about which drugs interact with insulin secretagogues to cause serious hypoglycemia, as well as the time-course of such interactions and the subgroups most susceptible to these DDIs. We will achieve this objective by taking a translational science approach to DDIs in which we 1) perform high-throughput simulation of potential DDIs based on pharmacologic knowledge;2) perform high-throughput screening of healthcare data;and then 3) confirm (or refute) and elucidate selected high-probability DDIs in an independent population by conducting in-depth pharmacoepidemiologic studies. This project will produce clinically-actionable knowledge about which drugs interact with secretagogues to cause severe hypoglycemia, and generalizable biological knowledge about the drugs and pathways involved in these interactions.
Drug-drug interactions (DDIs) are a major clinical and public health burden. Given that most individuals with type 2 diabetes mellitus take five or more medications, they are at high risk for clinically significant DDIs. Insulin secretagogues are used by many patients with diabetes, and have a high potential to cause serious hypoglycemia, especially in the setting of DDIs. This study will produce clinically-actionable knowledge about which drugs interact with insulin secretagogues to cause serious hypoglycemia, as well as the time-course of such interactions and the subgroups most susceptible to these DDIs.
|Alam, Khondoker; Pahwa, Sonia; Wang, Xueying et al. (2016) Downregulation of Organic Anion Transporting Polypeptide (OATP) 1B1 Transport Function by Lysosomotropic Drug Chloroquine: Implication in OATP-Mediated Drug-Drug Interactions. Mol Pharm 13:839-51|
|Cho, Doo-Yeoun; Shen, Joan H Q; Lemler, Suzanne M et al. (2016) Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers. Drug Metab Pharmacokinet 31:107-16|
|Leonard, Charles E; Han, Xu; Bilker, Warren B et al. (2016) Comparative risk of severe hypoglycemia among concomitant users of thiazolidinedione antidiabetic agents and antihyperlipidemics. Diabetes Res Clin Pract 115:60-7|
|Cheng, L; Li, L (2016) Systematic Quality Control Analysis of LINCS Data. CPT Pharmacometrics Syst Pharmacol 5:588-598|
|Ji, Xinyao; Small, Dylan S; Leonard, Charles E et al. (2016) The Trend-in-Trend Research Design for Causal Inference. Epidemiology :|
|Hennessy, S; Leonard, C E; Gagne, J J et al. (2016) Pharmacoepidemiologic Methods for Studying the Health Effects of Drug-Drug Interactions. Clin Pharmacol Ther 99:92-100|
|Jiang, Guanglong; Zhang, Shijun; Yazdanparast, Aida et al. (2016) Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer. BMC Genomics 17 Suppl 7:525|
|Leonard, C E; Bilker, W B; Brensinger, C M et al. (2016) Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics. Clin Pharmacol Ther 99:538-47|
|Li, Lang (2015) The potential of translational bioinformatics approaches for pharmacology research. Br J Clin Pharmacol 80:862-7|
|Flory, James; Haynes, Kevin; Leonard, Charles E et al. (2015) Proton pump inhibitors do not impair the effectiveness of metformin in patients with diabetes. Br J Clin Pharmacol 79:330-6|
Showing the most recent 10 out of 19 publications